Objective: To investigate the analysis of myostatin and therapeutic effects in uremia patients after different blood purification treatments. Methods: A total of 60 patients diagnosed with uremia in our hospital from May 2022 to May 2023 were retrospectively analyzed, all of whom were diagnosed with chronic uremia by doctors. The 60 patients were separated into a test group and a reference group of 30 each. The test group was treated with continuous blood purification, and the reference group was treated with intermittent blood therapy. The total treatment period was 5 weeks. Serum myostatin (MSTN), hemoglobin, red blood cells, serum creatinine, blood urea nitrogen (BUN) and other indicators were compared between the two groups of patients, and the differences between the two blood purification treatments were evaluated. Results: Comparing the treatment effects between the test group and the reference group, there are certain differences in the treatment effects, and the treatment cost of the reference group is obviously lower than that of the test group (P <0.05). The test group has a better effect on the MSTN clearance of patients than the reference group and has a better recovery of muscle function in patients. In the comparison of toxin removal effect, the overall performance of the reference group was worse than that of the test group (P <0.05). Serum phosphorus decreased significantly in both groups before and after treatment, especially in the test group, and the comparison had statistical significance (P <0.05). In the comparison of hemoglobin content, the test group decreased significantly before and after treatment (P <0.05). The two treatment options did not have much impact on the vital signs of the patients. Conclusion: Both schemes can alleviate the condition of uremia patients. Compared with indirect dialysis, continuous dialysis is more comprehensive, and the patient's remission effect is better within the same treatment time.